Derivation and Validation of Risk Prediction Model for 30-Day Readmissions Following Transcatheter Mitral Valve...

Area of Science:

• Cardiology
• Interventional Cardiology
• Health Services Research

Background:

• Transcatheter mitral valve repair (TMVr) improves outcomes but has a high 30-day readmission rate (around 15%).
• Reducing 30-day readmissions is crucial for optimizing patient care and healthcare resource utilization post-TMVr.

Purpose of the Study:

• To develop and validate a predictive tool for 30-day all-cause readmission following TMVr.
• To identify key clinical factors associated with increased readmission risk in TMVr patients.

Main Methods:

• Utilized the Nationwide Readmission Database (2014-2017) for a cohort of 8,339 TMVr patients.
• Developed a linear risk calculator and assessed its accuracy using internal calibration and bootstrapped calculations.
• Calculated root mean square error and mean absolute error to evaluate model performance.

Main Results:

• 14.2% of patients (1,246) experienced 30-day readmission.
• Key predictors identified: heart failure, atrial fibrillation, anemia, prolonged length of stay (≥4 days), acute kidney injury, non-home discharge, non-elective admission, and bleeding/transfusion.
• The prediction model demonstrated good discrimination (c-statistic: 0.63) and validation (c-statistic: 0.628).

Conclusions:

• A validated, user-friendly risk prediction tool for 30-day TMVr readmissions has been developed.
• This tool can effectively identify high-risk patients, enabling targeted discharge planning and potentially reducing healthcare costs.
• Optimizing discharge strategies based on this risk calculator can improve patient outcomes and resource management.